Valneva partners with CSL to commercialize vaccines in Germany

Valneva SE has partnered with CSL Seqirus to commercialize three brand-name vaccines in Germany, replacing a previous deal with Bavarian Nordic. The agreement involves CSL Seqirus manufacturing and distributing Valneva's vaccines in Germany. Valneva will receive royalties and milestone payments from CSL Seqirus for each vaccine sold in Germany. The deal is expected to expand Valneva's vaccine distribution in Germany and provide CSL Seqirus with new product offerings.

Valneva SE (NASDAQ: VALN; Euronext Paris: VLA), a specialty vaccine company, has announced an exclusive agreement with CSL Seqirus for the marketing and distribution of its three proprietary vaccines in Germany. This partnership, effective July 2025, will see CSL Seqirus commence commercialization of Valneva's single-dose chikungunya vaccine IXCHIQ®, Japanese Encephalitis vaccine IXIARO®, and cholera/ETEC vaccine DUKORAL®. The agreement replaces Valneva's previous deal with Bavarian Nordic, which is set to conclude at the end of December 2025 [1].

Under the new agreement, CSL Seqirus will handle the distribution and marketing of Valneva's vaccines in Germany for a period of three years. Valneva will receive royalties and milestone payments for each vaccine sold in Germany. The deal is expected to expand Valneva's vaccine distribution in Germany and provide CSL Seqirus with new product offerings.

Valneva's Chief Commercial Officer, Dipal Patel, expressed excitement about the partnership, noting that CSL's strong commercial presence in Germany will ensure seamless distribution of their vaccines in Europe's largest travel vaccine market [2]. The agreement aligns with Valneva's strategy of leveraging its in-house commercial infrastructure to focus on key markets in Europe.

Valneva's product sales reached €48.6 million in the first quarter of 2025, with €42.8 million coming from its proprietary vaccines. The company expects product sales to grow to €170-180 million in 2025, driving positive cash flows for its overall commercial business [1].

References:
[1] https://valneva.com/press-release/valneva-announces-exclusive-vaccine-marketing-and-distribution-agreement-for-germany-with-csl-seqirus/
[2] https://finance.yahoo.com/news/valneva-announces-exclusive-vaccine-marketing-050000313.html